5 results

  • fingolimod

    (FINGOLIMOD)
    Biocon Pharma Inc.
    Fingolimod capsules are indicated for treating relapsing forms of multiple sclerosis (MS) in patients aged 10 years and older, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.

  • mayzent

    (siponimod)
    Novartis Pharmaceuticals Corporation
    MAYZENT is indicated for treating relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.

  • ponvory

    (Ponesimod)
    Janssen Pharmaceuticals, Inc.
    PONVORY is indicated for treating relapsing forms of multiple sclerosis (MS) in adults, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.

  • tascenso odt

    (Fingolimod Lauryl Sulfate)
    Cycle Pharmaceuticals Ltd
    TASCENSO ODT is indicated for treating relapsing forms of multiple sclerosis (MS) in patients aged 10 and older, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.

  • zeposia

    (ozanimod hydrochloride)
    Celgene Corporation
    ZEPOSIA is indicated for the treatment of relapsing forms of multiple sclerosis (including clinically isolated syndrome, relapsing-remitting, and active secondary progressive disease) and moderately to severely active ulcerative colitis in adults.